loading
Proqr Therapeutics N V stock is traded at $2.26, with a volume of 446.75K. It is up +4.15% in the last 24 hours and up +11.33% over the past month. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.17
Open:
$2.18
24h Volume:
446.75K
Relative Volume:
1.11
Market Cap:
$237.78M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-5.9662
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-5.83%
1M Performance:
+11.33%
6M Performance:
+4.63%
1Y Performance:
+20.21%
1-Day Range:
Value
$2.1076
$2.39
1-Week Range:
Value
$2.1076
$2.47
52-Week Range:
Value
$1.07
$4.62

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name
Name
Proqr Therapeutics N V
Name
Phone
-
Name
Address
-
Name
Employee
166
Name
Twitter
@proqr
Name
Next Earnings Date
2025-03-14
Name
Latest SEC Filings
Name
PRQR's Discussions on Twitter

Compare PRQR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PRQR
Proqr Therapeutics N V
2.26 228.59M 7.05M -30.43M 21.84M -0.3788
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-29-25 Resumed Cantor Fitzgerald Overweight
Apr-29-25 Initiated Evercore ISI Outperform
Mar-10-25 Upgrade Citigroup Neutral → Buy
Jan-10-25 Initiated Oppenheimer Outperform
Oct-29-24 Upgrade Raymond James Outperform → Strong Buy
Nov-08-23 Upgrade Chardan Capital Markets Neutral → Buy
Mar-30-23 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Dec-22-22 Upgrade Cantor Fitzgerald Neutral → Overweight
Feb-14-22 Downgrade Citigroup Buy → Neutral
Feb-11-22 Downgrade Raymond James Strong Buy → Mkt Perform
Feb-11-22 Downgrade Stifel Buy → Hold
Feb-01-22 Initiated Raymond James Strong Buy
May-03-21 Initiated Stifel Buy
Mar-25-21 Reiterated Citigroup Buy
Nov-03-20 Resumed Cantor Fitzgerald Overweight
Mar-12-19 Reiterated Chardan Capital Markets Buy
Dec-19-18 Initiated RBC Capital Mkts Outperform
Nov-15-18 Initiated Citigroup Buy
Sep-19-18 Initiated Evercore ISI Outperform
Sep-26-17 Reiterated JMP Securities Mkt Outperform
Jun-20-16 Initiated Chardan Capital Markets Neutral
Oct-15-14 Initiated Deutsche Bank Buy
Oct-13-14 Initiated H.C. Wainwright Buy
View All

Proqr Therapeutics N V Stock (PRQR) Latest News

pulisher
05:28 AM

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

05:28 AM
pulisher
03:58 AM

Is ProQR Therapeutics N.V. a good long term investmentFree Popular Stock Recommendations - PrintWeekIndia

03:58 AM
pulisher
Jul 24, 2025

Is ProQR Therapeutics N.V. stock a growth or value playVerified Return Tips - Newser

Jul 24, 2025
pulisher
Jul 24, 2025

Will ProQR Therapeutics N.V. stock benefit from interest rate changesAccelerated financial growth - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

What drives ProQR Therapeutics N.V. stock priceStrong return on assets - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about ProQR Therapeutics N.V. stockUnprecedented profit potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 21, 2025

Owning 32% shares,institutional owners seem interested in ProQR Therapeutics N.V. (NASDAQ:PRQR), - Yahoo Finance

Jul 21, 2025
pulisher
Jul 19, 2025

ProQR Therapeutics N.V. Stock Analysis and ForecastDynamic investment growth - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 17, 2025

ProQR stock rating reiterated by Cantor Fitzgerald ahead of key 2H25 data - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 15, 2025

Why ProQR Therapeutics N.V. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How ProQR Therapeutics N.V. stock performs during market volatilityProven Win Setups - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes ProQR Therapeutics N.V. stock price move sharplyFree Wealth-Building Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) high institutional ownership speaks for itself as stock continues to impress, up 16% over last week - simplywall.st

Jul 15, 2025
pulisher
Jul 14, 2025

ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares Acquired by OneDigital Investment Advisors LLC - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat

Jul 11, 2025
pulisher
Jul 10, 2025

Vontobel Holding Ltd. Invests $48,000 in ProQR Therapeutics N.V. (NASDAQ:PRQR) - Defense World

Jul 10, 2025
pulisher
Jul 07, 2025

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com Australia

Jul 07, 2025
pulisher
Jul 06, 2025

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles By Investing.com - Investing.com South Africa

Jul 06, 2025
pulisher
Jul 03, 2025

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat

Jul 03, 2025
pulisher
Jun 30, 2025

ProQR Therapeutics' (PRQR) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat

Jun 30, 2025
pulisher
Jun 28, 2025

ProQR Therapeutics (NASDAQ:PRQR) Given Market Outperform Rating at JMP Securities - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

PRQR: Cantor Fitzgerald Reiterates Overweight Rating | PRQR Stoc - GuruFocus

Jun 27, 2025
pulisher
Jun 27, 2025

ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target By Investing.com - Investing.com Canada

Jun 27, 2025
pulisher
Jun 27, 2025

ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target - Investing.com

Jun 27, 2025
pulisher
Jun 26, 2025

ProQR submits clinical trial application for RNA editing therapy By Investing.com - Investing.com India

Jun 26, 2025
pulisher
Jun 26, 2025

ProQR Seeks EU Approval for Liver Cell Protein Trial - MarketScreener

Jun 26, 2025
pulisher
Jun 26, 2025

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP - GlobeNewswire

Jun 26, 2025
pulisher
Jun 26, 2025

ProQR Advances First RNA Editing Therapy to Clinical Trials for Liver Disease | PRQR Stock News - Stock Titan

Jun 26, 2025
pulisher
Jun 15, 2025

Bank of America Corp DE Boosts Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jun 15, 2025
pulisher
Jun 13, 2025

ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - simplywall.st

Jun 13, 2025
pulisher
Jun 13, 2025

Equities Analysts Offer Predictions for PRQR FY2026 Earnings - MarketBeat

Jun 13, 2025
pulisher
Jun 11, 2025

Research Analysts Set Expectations for PRQR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Buys Shares of 11,400 ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $8.00 - MarketBeat

Jun 09, 2025
pulisher
Jun 09, 2025

ProQR Therapeutics (NASDAQ:PRQR) Shares Sold by Two Sigma Advisers LP - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Squarepoint Ops LLC Grows Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Jun 06, 2025

Proqr Therapeutics N V Stock (PRQR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Cap:     |  Volume (24h):